Application Basis of Combining Antiangiogenic Therapy with Radiotherapy and Immunotherapy in Cancer Treatment

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Nov 28

PMID 36439496

Authors

Meng Yuan

Yirui Zhai

Zhouguang Hui

Affiliations

Soon will be listed here.

Abstract

How to further optimize the combination of radiotherapy and immunotherapy is among the current hot topics in cancer treatment. In addition to adopting the preferred dose-fractionation of radiotherapy or the regimen of immunotherapy, it is also very promising to add antiangiogenic therapy to this combination. We expound the application basis of cancer radiotherapy combined with immunotherapy and antiangiogenic therapy.

Citing Articles

Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review.

Ding R, Jiao H, Piao Y, Tian W Medicine (Baltimore). 2023; 102(39):e35506.

PMID: 37773801 PMC: 10545358. DOI: 10.1097/MD.0000000000035506.

Recombinant Endostatin as a Potential Radiosensitizer in the Treatment of Non-Small Cell Lung Cancer.

Cunningham C, Bolcaen J, Bisio A, Genis A, Strijdom H, Vandevoorde C Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259367 PMC: 9961924. DOI: 10.3390/ph16020219.

References

Manegold P, Paringer C, Kulka U, Krimmel K, Eichhorn M, Wilkowski R . Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res. 2008; 14(3):892-900. DOI: 10.1158/1078-0432.CCR-07-0955. View

Willett C, Kozin S, Duda D, Tomaso E, Kozak K, Boucher Y . Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol. 2006; 33(5 Suppl 10):S35-40. PMC: 2686124. DOI: 10.1053/j.seminoncol.2006.08.007. View

Gabrilovich D, Nagaraj S . Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9(3):162-74. PMC: 2828349. DOI: 10.1038/nri2506. View

Jain R . Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307(5706):58-62. DOI: 10.1126/science.1104819. View

Dewhirst M, Cao Y, Moeller B . Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008; 8(6):425-37. PMC: 3943205. DOI: 10.1038/nrc2397. View

Salem A, Asselin M, Reymen B, Jackson A, Lambin P, West C . Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome. J Natl Cancer Inst. 2017; 110(1). DOI: 10.1093/jnci/djx160. View

Lee P, Chandel N, Simon M . Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol. 2020; 21(5):268-283. PMC: 7222024. DOI: 10.1038/s41580-020-0227-y. View

Kamrava M, Bernstein M, Camphausen K, Hodge J . Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?. Mol Biosyst. 2009; 5(11):1262-70. PMC: 6309404. DOI: 10.1039/b911313b. View

Holash J, Maisonpierre P, Compton D, Boland P, Alexander C, Zagzag D . Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999; 284(5422):1994-8. DOI: 10.1126/science.284.5422.1994. View

10.

Pierini S, Mishra A, Perales-Linares R, Uribe-Herranz M, Beghi S, Giglio A . Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression. J Immunother Cancer. 2021; 9(2). PMC: 7875275. DOI: 10.1136/jitc-2020-001636. View

11.

Lee C, Heijn M, Di Tomaso E, Ancukiewicz M, Koike C, Park K . Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000; 60(19):5565-70. View

12.

Huang G, Chen L . Tumor vasculature and microenvironment normalization: a possible mechanism of antiangiogenesis therapy. Cancer Biother Radiopharm. 2008; 23(5):661-7. DOI: 10.1089/cbr.2008.0492. View

13.

Gorski D, Beckett M, Jaskowiak N, Calvin D, Mauceri H, Salloum R . Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999; 59(14):3374-8. View

14.

Huang Y, Yuan J, Righi E, Kamoun W, Ancukiewicz M, Nezivar J . Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012; 109(43):17561-6. PMC: 3491458. DOI: 10.1073/pnas.1215397109. View

15.

Cao Y, Li C, Moeller B, Yu D, Zhao Y, Dreher M . Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. Cancer Res. 2005; 65(13):5498-505. DOI: 10.1158/0008-5472.CAN-04-4553. View

16.

Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti H . Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature. 2008; 453(7193):410-4. DOI: 10.1038/nature06868. View

17.

Dings R, Loren M, Heun H, McNiel E, Griffioen A, Mayo K . Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 2007; 13(11):3395-402. PMC: 2914684. DOI: 10.1158/1078-0432.CCR-06-2441. View

18.

Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J . Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer. 2009; 100(7):1111-9. PMC: 2670006. DOI: 10.1038/sj.bjc.6604965. View

19.

Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O . VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2012; 73(2):539-49. DOI: 10.1158/0008-5472.CAN-12-2325. View

20.

Zhang K, Yang S, Zhu Y, Mo A, Zhang D, Liu L . Protection against acute radiation-induced lung injury: a novel role for the anti-angiogenic agent Endostar. Mol Med Rep. 2012; 6(2):309-15. DOI: 10.3892/mmr.2012.903. View